O. Sanchez (Paris, France), E. Gruenig (Heidelberg, Germany)
The victim potential of sitaxentan: metabolism by human CYP450 enzymes
F. Stavros, W. Kramer, B. Ogilvie, A. Parkinson (Houston, North Potomac, Lenexa, United States Of America)
|   |
The perpetrator potential of sitaxentan based on its ability to inhibit human cytochrome P450 (CYP) enzymes
F. Stavros, W. Kramer, B. Ogilvie, A. Parkinson (Houston, North Potomac, Lenexa, United States Of America)
| |
The perpetrator potential of sitaxentan: human CYP enzyme induction
F. Stavros, W. Kramer, B. Ogilvie, A. Parkinson (Houston, North Potomac, Lenexa, United States Of America)
| |
Improvement of exercise capacity due to beta blocker treatment in the model of MCT induced pulmonary hypertension
S. Schroll, T. Lange, M. Arzt, D. Sebah, B. Stoelcker, M. Pfeifer (Regensburg, Donaustauf, Germany)
| |
Systemic inflammation and pulmonary hypertension in patients with bronchial asthma
N. Karoli, A. Rebrov, A. Roshina (Saratov, Russian Federation)
| |
New markers of endothelial dysfunction in patients with bronchial asthma with and without pulmonary hypertension
N. Karoli, A. Roshina, A. Rebrov, T. Martinova, L. Novikova (Saratov, Russian Federation)
| |
Pulmonary hypertension and endothelial dysfunction in patients with bronchial asthma
N. Karoli, A. Roshina, A. Rebrov, O. Karpova, L. Lukianova (Saratov, Russian Federation)
| |
Day time pulmonary hypertension in patients with obstructive sleep apnea hypopnea syndrome
Z. He, X. Guo (Beijing, China)
| |
Comparison between transthoracic doppler echocardiography and right heart catheterization for pulmonary hypertension evaluation
M. Gazzana, A. John, S. Fagondes, M. Wainstein, D. Spader, D. Rigotti, S. Menna Barreto (Porto Alegre – Rio Grande do Sul, Brazil)
| |
An international investigation into the health status of COPD sufferers
A. Nadjar, F. Boucher, F. D. Uva, M. Garfield, T. Van der Molen (Lyon, France; Milford, United States Of America; Groningen, Netherlands)
| |
Characterization of elastin degradation biomarkers in chronic obstructive pulmonary disease (COPD)
Y. Y. Lin, S. Ma, J. He, J. O. Cantor, G. M. Turino (New York, United States Of America)
| |
Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease
O. Korzh, S. Krasnokutskiy (Kharkov, Ukraine)
| |
Clinical significance of P wave amplitude and axis in ECG of COPD patients during acute exacerbations
C. Ravindran, P. James, K. Moyinkutty, K. A. K. Abdul, C. C. Velayudhan (Calicut, Kerala, India)
| |
Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma
H. Koskela, M. Purokivi, K. Kontra, A. Taivainen, H. Tukiainen (Kuopio, Finland; Kuopio, Ethiopia)
| |
Efficiency of isolated hypertrophic rat papillary muscle is lower than control
Y. Y. Wong, L. Handoko, F. de Man, K. Mouchaers, A. Vonk-Noordegraaf, W. van der Laarse (Amsterdam, Netherlands)
| |
Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension
R. Voswinckel, N. Gross, F. Reichenberger, M. Thamm, B. Karadas, H. Gall, H. Nef, F. Grimminger, W. Seeger, H. A. Ghofrani (Giessen, Germany)
| |
Maximal cardiopulmonary exercise testing in children with pulmonary hypertension
G. Smith, J. Russell, J. Reyes, T. Humpl (Toronto, ON, Canada)
| |
Pulmonary arterial hypertension induces ECG changes associated with arrhythmia propensity
K. T. B. Mouchaers, I. R. Henkens, A. Boonstra, M. J. Schalij, E. E. van der Wall, C. A. Swenne, H. W. Vliegen, A. Vonk Noordegraaf (Amsterdam, Leiden, Netherlands)
| |
Thrombophilia in patients with idiopathic pulmonary thromboembolism vs associated with risk factors
N. Marina, F. Uresandi, G. Iruin, V. Cabriada, B. Gomez, P. Sobradillo, S. Pedrero (Baracaldo, Spain)
| |